RecruitMe Clinical Trial

A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
A study for patients with biliary or gallbladder cancer using study drug DKN-01
Sponsor:HealthCare Pharmaceuticals
Enrolling:Male and Female Patients
Age Range:Between 30 and 99 years old
IRB Number:AAAO7003
U.S. Government ID:NCT02375880
Contact: Reaundra McCullough-Roach: 212-304-6337 / rm3551@cumc.columbia.edu
Additional Study Information:

This research study is being done to see how an investigational drug called DKN-01 combined with standard cancer drugs (gemcitabine and cisplatin) works in people with biliary or gallbladder cancer. DKN-01 is an antibody that blocks the function of another protein in the body called dickkopf-1 (Dkk-1). Too much (over expression) of the Dkk-1 protein has been implicated in tumor growth and disease progression and elevated levels may play a role in the growth and spread of biliary, gallbladder, and other cancers. DKN-01 is being studied in multiple investigational research studies including this one to see whether it can slow tumor growth and help patients with different types of cancer.

This study is closed
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Reaundra McCullough-Roach
Email: rm3551@cumc.columbia.edu
Phone: 212-304-6337